Skip to main content
Premium Trial:

Request an Annual Quote

DNA Tests: It's Like the Wild West Out Here

Newsweek has an article about consumer genomics -- or, more specifically, the rise in genetic testing targeted at people in the mainstream. Pegged to the Navigenics launch extravaganza here in New York, the article asks whether there's solid science "behind all the hype." The story also warns consumers about a murky regulatory landscape that may affect the quality of results they can expect to receive: "While the government mandates that genetic tests be performed in certified labs, not all are, and there's little to no oversight of a given test's accuracy or clinical usefulness."

And if you want to read more about the Navigenics SoHo blowout, check out this article in the New York Times.

 

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.